There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on TRACON Pharmaceuticals (TCON – Research Report) and IN8bio (INAB – Research Report) with bullish sentiments.
IN8bio (INAB)
H.C. Wainwright analyst Swayampakula Ramakanth maintained a Buy rating on IN8bio today and set a price target of $14.00. The company’s shares closed last Wednesday at $1.06, close to its 52-week low of $0.65.
According to TipRanks.com, Ramakanth is a 4-star analyst with an average return of
IN8bio has an analyst consensus of Strong Buy, with a price target consensus of $8.63.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on TCON:
- TRACON Pharmaceuticals Announces Reverse Stock Split
- Tracon Pharmaceuticals announces 1-for-20 reverse stock split
- Tracon Pharmaceuticals price target lowered to $3 from $6 at H.C. Wainwright
- Tracon says IDMC reccommends ENVASARC Phase 2 trial continue ‘as planned’
- Two new option listings and option delistings on March 25th
